GenomeWeb: Unexpected Prevalence of High-Risk HPV Types Demonstrates Utility of Zeesan Biotech Assay in Low-Resource Setting

May 29, 2019

By GenomeWeb Staff Reporter

NEW YORK (GenomeWeb) – An evaluation of an HPV typing assay from Zeesan Biotech has shown the firm’s test kit can be incorporated successfully into an inexpensive screening protocol and run near patients in a low-resource setting.

Among a population of female factory workers in Honduras, the Zeesan HPV typing test detected a low prevalence of high-risk HPV types 16 and 18, but an unexpectedly high prevalence of high-risk type 58.

The study (Screening for Human Papillomavirus in a Low-and Middle-Income Country), which was published this month in the Journal of Global Oncology, was a collaboration between researchers at Dartmouth College and scientists and clinicians in San Pedro Sula, Honduras. It evaluated a PCR-based, CE-marked kit called the MeltPro High Risk HPV Genotyping Assay from Zeesan Biotech.

The study also incorporated a real-time PCR instrument called the SLAN-96, also from Zeesan Biotech.

Gregory Tsongalis, director of the laboratory for clinical genomics and advanced technology (CGAT) at Dartmouth, said his team initially tried to develop its own HPV genotyping assay for low-resource settings, but then learned about the Zeesan test and decided to assess it.

This is a very robust assay with relatively high throughput and [it] can differentiate between all high-risk and low-risk HPV types in two separate assays,” Tsongalis said in an email. Still, the team put the assay through “a very rigorous validation” before deploying it, he added.

For full story, please read it on GenomeWeb or contact info@zsandx.com.

About Gregory J. Tsongalis

Dr. Tsongalis is the director of the molecular pathology laboratory and co-director of the translational research program in the Geisel School of Medicine at Dartmouth College, the Dartmouth Hitchcock Medical Center, and the Norris Cotton Cancer Center in Lebanon, N.H.

About Zeesan Biotech

Xiamen Zeesan Biotech Co., Ltd., is an ISO 13485:2003-certified manufacturer specialized in providing an integrated solution for personalized medicine, including molecular diagnostic instruments, reagents, and consumable materials. Our products are widely used in medical diagnosis for treatment of tuberculosis, leukemia, cervical cancer, and so on. More than 40 products have got CFDA approval and 18 products are CE marked for clinical use in Europe. Zeesan products are shipped to more than 30 countries with good feedback.

 


INQUIRY DETAILS *

INQUIRY NOW
  • captcha